[Dialysis amyloidosis syndrome in patients aged over 55 years and undergoing a hemodialysis program].
The clinical-and-biochemical signs of the dialysis amyloidosis syndrome were studied in two groups of patients with chronic renal insufficiency (CRI), who have been undergoing a multi-year renal-substitutive therapy (program-type hemodialysis). The first group comprised 77 adult patients (aged 18-40), the second group comprised 49 "elderly" patients (aged 55-73). Apart from the standard analyses, the dynamics of beta 2-microglobulin (beta 2-M) was studied in the blood of patients. Specific features in the development of the syndrome of dialysis amyloidosis were described; they correlated with the level of beta 2-M, with a duration of program-type hemodialysis, with the elderly age of patients, with variants of renal pathologies, and with an concomitant diabetes mellitus.
Il'in
A P
AP
Bogoiavlenskiĭ
V F
VF
Gazizov
R M
RM
Stepanov
P V
PV
D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000097:blood / Q000209:etiology*; D048909:Diabetes Complications; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000378:metabolism / Q000628:therapy; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D013577:Syndrome; D013997:Time Factors; D001613:beta 2-Microglobulin / Q000032:analysis
D001613:beta 2-Microglobulin
Sindrom dializnogo amiloidoza u patsientov starshe 55 let, nakhodiashchikhsia na programmnom gemodialize.